Modified exendins and exendin agonists

Details Modified exendins and exendin agonists Modified exendins and exendin agonists

2005-06-30

2011-11-15

Desai, Anand (Department: 1656)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Particulate form

C514S002600, C514S003100, C514S012200, C424S278100, C530S300000

Reexamination Certificate

active

08057822

ABSTRACT:
Novel modified exendins and exendin agonists having an exendin or exendin agonist linked to one or more polyethylene glycol polymers, for example, and related formulations and dosages and methods of administration thereof are provided. These modified exendins and exendin agonists, compositions and methods are useful in treating diabetes and conditions that would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying or inhibiting food intake.

REFERENCES:
patent: 4179337 (1979-12-01), Davis
patent: 4766106 (1988-08-01), Katre et al.
patent: 5122614 (1992-06-01), Zalipsky
patent: 5176918 (1993-01-01), Jones
patent: 5214131 (1993-05-01), Sano et al.
patent: 5264372 (1993-11-01), Beaumont
patent: 5424286 (1995-06-01), Eng
patent: 5428128 (1995-06-01), Mensi-Fattohi et al.
patent: 5686511 (1997-11-01), Bobo
patent: 5747639 (1998-05-01), Seeley
patent: 5824784 (1998-10-01), Kinstler et al.
patent: 5839443 (1998-11-01), Rose et al.
patent: 6051557 (2000-04-01), Drucker
patent: 6268343 (2001-07-01), Knudson et al.
patent: 6284725 (2001-09-01), Coolidge et al.
patent: 6376549 (2002-04-01), Fine et al.
patent: 6429197 (2002-08-01), Coolidge et al.
patent: 6451974 (2002-09-01), Hansen
patent: 6528486 (2003-03-01), Larsen et al.
patent: 6723530 (2004-04-01), Drucker
patent: 6753165 (2004-06-01), Cox et al.
patent: 6767887 (2004-07-01), Hoffmann et al.
patent: 6872700 (2005-03-01), Young et al.
patent: 6924264 (2005-08-01), Prickett et al.
patent: 6924624 (2005-08-01), Baur et al.
patent: 6956026 (2005-10-01), Beeley et al.
patent: 6982248 (2006-01-01), Coolidge et al.
patent: 7153825 (2006-12-01), Young et al.
patent: 7189690 (2007-03-01), Rosen et al.
patent: 7226990 (2007-06-01), Knudsen et al.
patent: 7259136 (2007-08-01), Hathaway et al.
patent: 7271149 (2007-09-01), Glaesner et al.
patent: 2001/0047084 (2001-11-01), Knudsen et al.
patent: 2002/0147131 (2002-10-01), Coolidge et al.
patent: 2005/0026834 (2005-02-01), Cox et al.
patent: 2006/0030528 (2006-02-01), Hathaway et al.
patent: 2007/0037750 (2007-02-01), Young et al.
patent: 0619322 (1994-10-01), None
patent: WO 95/70989 (1995-03-01), None
patent: WO 97/46584 (1995-03-01), None
patent: WO 98/05351 (1998-02-01), None
patent: WO 98/08871 (1998-03-01), None
patent: WO 98/30231 (1998-07-01), None
patent: WO 99/07404 (1999-02-01), None
patent: WO 9907404 (1999-02-01), None
patent: WO 99/25727 (1999-05-01), None
patent: WO 99/25728 (1999-05-01), None
patent: WO 99/43708 (1999-09-01), None
patent: WO 99/46283 (1999-09-01), None
patent: WO 00/41548 (2000-07-01), None
patent: WO 00/66629 (2000-11-01), None
Heithier et al. (1988) Fluorescent glucagon derivatives. I. Synthesis and characterisation of fluorescent glucagon derivatives. Biochim. Biophys. Acta. vol. 971, pp. 298-306.
Chicchi et al. (1997) Fluorescein-Trp25-exendin-4, a biologically active fluorescent probe for the human GLP-1 receptor. Peptides. vol. 18, pp. 319-321.
Tota etal. (1995) Interaction of [fluorescein-Trp25]glucagon with the human glucagon receptor expressed in Drosophila Schneider 2 cells. J. Biol. Chem. vol. 270, pp. 26466-26472.
Application note (no date) “molecular weight determinations of polymers and polysaccharides using the zetasizer nano system”, pp. 1-3.
Montrose-Rafizadeh et al. (1997) High potency antagonists of the pancreatic glucagon-like peptide-1 receptor. J. Biol. Chem. vol. 272, No. 34, pp. 21201-21206.
Delgado et al. (1992) The uses and properties of PEG-linked proteins. Crit. Rev. Ther. Drug Carrier Syst. vol. 9, Nos. 3-4, pp. 249-304.
Edwards et al., “Glucagon-Like Peptide 1 Has a Physiological Role in the Control of postprandial Glucose in Humans—Studies with the Antagonist Exendin 9-39,”Diabetes48:86-93 (1999).
Montrose-Rafizadeh et al., “High Potency Antagonists of the pancreatic Glucagon-like Peptide-1 Receptor,”J. Biol. Chem. 272(34):21201-21206 (1997).
Saifer et al., “Improved Conjugation of Cytokines Using High Molecular Weight poly(ethylene glycol): PEG-GM-CSF as a Prototype,”Polymer Reprints38(1):576-577 (1997) (American Chemical Society).
Thorens et al., “Cloning and Functional Expression of the Human Islet GLP-1 Receptor—Demonstration that Exendin-4 is an Agonist and Exendin-(9-39) an Antagonist of the Receptor,” Diabetes 42:1678-1682 (1993).
Byrne et al., “Lessons from human studes with glucagon-like peptide-1: Potential of the gut hormone for clinical use,” in: Insufintropic Gut Hormones Glucagon-Like Peptide 1, Fehmann, HC Editor, Basel, Switzerland: Keroer, pp. 219-233 (1997).
Broca et al., “Hydroxyisoleucine: Experimental evidence of Its Insulfinotropic and antidiabetic properties,” Am. J. Physiol. 277:617 (1999).
Chen et al., “Tissue-specific Expression of Unique mRNAs that Encode Proglucagon-derived Peptides or Exendin 4 in the Lizard,” J. Biol. Chem. 272(7):4108-4115 (1997).
Creutzfeldt et al., “Glucegonstatic Actions and Reduction of Fasting Hyperglycemia by Exogenous Glucegon-Like Peptide 1(7-38) Amide in Type I Diabetic Patients,” Diabetes Care 19(6):580-586 (1996).
D'Alessio et al., “Elimination of the Action of Glucagon-Like Peptide 1 Causes an Impalment of Glucose Tolerance After Nutrient Ingestion by Healthy Baboons,” J. Clin. Invest. 97:133-38 (1996).
Delgado et al., “The Uses and Properties of PEG-Linked Proteins,” Critical Reviews in Therapeutic Drug Carrier Systems 9(3,4)249-304 (1992).
Egan et al., “Glucagon-Like Peptide-1 Restores Acute Phase Insulin Release to Aged Rats,” Diabetologia 40(Supp 1):A130 (1997).
Elssele et al., “Rat Gastric Somatostatin and Gastrin Release: Interactions of Exendln-4 and Truncated Glucagon-Like Peptide-1 (GLP-1) Amide,” Life Sci., 55:629-34 (1994).
Eng et al., “Isolation and Characterization of Exendin-4, an Exendin-3 Analogue, from Heloderma suspectum Venom,” J. Biol. Chem. 267:7402-05 (1992).
Eng et al., “Purification and Structure of Exendin-3 a New Pancreatic Secretagogue Isolated from Heloderma horridum Venom,” J. Biol. Chem. 265:20259-62 (1990).
Eng., “Prolonged Effect of Exendin-4 on Hyperglycemia of db/db mice,” Diabetes 45(Supp 2):152A (abstract 554) (1996).
Francis et al., “PEGylation of cytokines and other Therapeutic Proteins and Peptides: The Importance of Biological Optimisation of Coupling Techniques,” Intl J. Hematology 68:1-18 (1998).
Goke et al., “Exendin-4 Is a High Potency Agonist and Truncated Exendin-(9-39)-amide an Antagonist at the Glucagon-like Peptide 1-(7-36)-amide Receptor of Insulin-secreting-Cells,” J. Biol. Chem. 268:19650-65 (1993).
Gombotz et al., “Biodegradable Polymers for Protein and Peptide Drug Delivery,” Bioconjugate Chemistry 6:332-351 (1995).
Halaas et al., “weight-Reducing Effects of the Plasma Protein Encoded by the Obese Gene” Science 269:543-546 (1995).
Hudecz et al., “Synthesis, Conformation, Biodistribution, and In Vitro Cytotoxicity of Daunomydn-Branced Polypeptide Conjugates,” Bioconjugate Chemistry 3:49-57 (1992).
Malhotra et al., “Exendin-4, a new peptide from Heloderma suspectum venom, potentiates cholecystokinin-induced amylase release from rat pancreatic acid,” Regulatory Peptides 41:149-56 (1992).
Meurer et al., Properties of native and in vitro glycosylated forms of the glucagons-like peptide-1 receptor antagonist exendin (9-39), Metabolism Clinical and Experimental 48(6):718-724 (1999).
O'Halloran et al., “Glucagon-like peptide-1 (7-36)-NH2 : A physiological inhibitor of gastric acid secretion in man,” J.Endocrinol 126(1):169-73 (1990).
Orskov et al., “Biological Effects and Metabolic Rates of Glucagordlike Peptide-1 7-36 Amide and glucagonlike Peptide-1 7-37 in Health Subjects are Indistinguishable,” Diabetes 42:658-61.(1993).
Pelleymounter et al., Effects of the obese gene product on body weight regulation in ob/ob mice, Science 269:540-543 (1995).
Pr

Affiliated with

Also associated with

Rating

Modified exendins and exendin agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Modified exendins and exendin agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified exendins and exendin agonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4296461